Advaxis (Advaxis) LT-Debt-to-Total-Asset : 0.07 (As of Mar. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Advaxis LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Advaxis's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 0.07.

Advaxis's long-term debt to total assets ratio increased from Jan. 2022 (0.00) to Mar. 2023 (0.07). It may suggest that Advaxis is progressively becoming more dependent on debt to grow their business.

Advaxis LT-Debt-to-Total-Asset Historical Data

The historical data trend for Advaxis's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis LT-Debt-to-Total-Asset Chart

Advaxis Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

Advaxis Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Mar23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	0.07

Advaxis LT-Debt-to-Total-Asset Calculation

Advaxis's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2022 is calculated as

LT Debt to Total Assets (A: Oct. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Oct. 2022 )	/	Total Assets (A: Oct. 2022 )
	=	0	/	25.93
	=	0.00

Advaxis's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )	/	Total Assets (Q: Mar. 2023 )
	=	1.41	/	20.995
	=	0.07

Advaxis (OTCPK:ADXS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Advaxis LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Advaxis's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Advaxis (Advaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540

Website

https://www.advaxis.com

Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.

Executives

Roy Golan	officer: Chief Financial Officer	24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly	director	C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach	director	C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel	10 percent owner	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman	officer: Chief Accounting Officer	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070